Pediatric Migraine clinical trials

Explore recruiting pediatric migraine clinical trials.

Recruiting pediatric migraine studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pediatric Migraine trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Longterm, openlabel (doseblinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine

Italy, Portugal, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Poland, Hungary, Italy, Netherlands, Denmark, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951013 - AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Hungary, Italy, Spain, Czechia, Poland, Finland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17years) for the preventive treatment of chronic migraine.

Spain, Portugal, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

Italy, Germany, Hungary, Poland, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])

Germany, Portugal, Italy, Belgium, Spain, Hungary +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pediatric Migraine trials by city

Pediatric Migraine in Toronto Pediatric Migraine in Vancouver Pediatric Migraine in Montreal Pediatric Migraine in Calgary Pediatric Migraine in Edmonton Pediatric Migraine in Ottawa Pediatric Migraine in Winnipeg Pediatric Migraine in Quebec City Pediatric Migraine in Hamilton Pediatric Migraine in Kitchener Pediatric Migraine in London Pediatric Migraine in Halifax Pediatric Migraine in New York Pediatric Migraine in Los Angeles Pediatric Migraine in Chicago Pediatric Migraine in Houston

Pediatric Migraine clinical trials

Recruiting pediatric migraine studies right now

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Mind Body Balance for Pediatric Migraine

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

Assessment of the Effectiveness of Virtual Reality as a Learning Tool for Relaxation Techniques in Reducing Pediatric Migraines and Tension Type Headache

Responding With Evidence and Access for Childhood Headaches

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducation for Adolescents With Migraine

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine

Also recruiting in Europe

Longterm, openlabel (doseblinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

C4951013 - AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17years) for the preventive treatment of chronic migraine.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])

Pediatric Migraine trials by city

Other conditions